Perfuse Therapeutics Announces Initiation of Enrollment to Ph2a Portion of the Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

dose cohort has shown promising results with no significant safety concerns. Now, Perfuse Therapeutics is excited to move forward with the Phase 2a portion of the clinical trial. &nbsp Glaucoma is a progressive eye disease that can lead to irreversible vision loss if left untreated. Current treatment options for glaucoma focus on reducing intraocular pressure (IOP) to slow down the progression o..